← Back to front page
United States · Platforms & data · Benzinga

AstraZeneca Secures Dual Rare Disease and Bladder Cancer Approvals Across US, Europe

Published by Benzinga · United States 17 min ago
AstraZeneca Secures Dual Rare Disease and Bladder Cancer Approvals Across US, Europe
Benzinga

Detailed summary

Regulators in the U.S. and European Union handed AstraZeneca Plc (NYSE:AZN) major regulatory wins across rare neuromuscular disease and oncology. The agencies cleared Klygefa for…

Read the full article on Benzinga Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.benzinga.com)

Also worth reading